Detection and Genotyping of Human Papillomavirus in Urine Samples from Unvaccinated Male and Female Adolescents in Italy by S. Bianchi et al.
Detection and Genotyping of Human Papillomavirus in
Urine Samples from Unvaccinated Male and Female
Adolescents in Italy
Silvia Bianchi1, Elena Rosanna Frati1, Donatella Panatto2,7, Marianna Martinelli1, Daniela Amicizia2,7, Carla
Maria Zotti3, Morena Martinese3, Paolo Bonanni4, Sara Boccalini4, Rosa Cristina Coppola5, Giuseppina
Masia5, Angelo Meloni5, Paolo Castiglia6, Andrea Piana6, Roberto Gasparini2,7, Elisabetta Tanzi1,7*
1 Department of Biomedical Sciences for Health, University of Milan, Milan, Italy, 2 Department of Health Sciences, University of Genoa, Genoa, Italy,
3 Department of Public Health and Paediatrics Sciences, University of Turin, Turin, Italy, 4 Department of Health Sciences, University of Florence, Florence,
Italy, 5 Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy, 6 Department of Biomedical Sciences, University of
Sassari, Sassari, Italy, 7 Inter-University Centre for Research on Influenza and other Transmitted Infections (CIRI-IT), Department of Health Sciences, University
of Genoa, Genoa, Italy
Abstract
The introduction of vaccination against Human Papillomavirus (HPV) in adolescent girls in 2006 has focused
virological surveillance on this age group. As few studies have evaluated HPV infections in young populations, further
data are needed in order to improve and extend prophylactic policy and to monitor epidemiological changes. The
present study aimed at evaluating overall and type-specific HPV prevalence in both female and male adolescents in
Italy. HPV DNA detection and genotyping was performed on urine samples collected from 870 unvaccinated
adolescents (369 females, 501 males, 11-18 years of age) in five cities in Italy. Following DNA extraction by means
of a commercial kit (NucliSENS®-miniMAG®, bioMérieux), the L1 gene fragment was PCR amplified and genotyped
by restriction fragment length polymorphism analysis. HPV DNA was detected in 1.5% of all samples, and in 3% and
0.4% of samples from females and males, respectively. In approximately 70% of HPV DNA positive adolescents, the
infection was due to a single genotype, with 88.9% of genotypes belonging to the HR-clade. The only two HPV-
positive boys (14 and 18 years old) had HPV-70 genotype. Only one of the 11 HPV-infected girls was in the 11-14
age-group. HPV prevalence was 4.2% in girls aged 15-18 years and 60% of infections were due to vaccine types
HPV-16 or HPV-6/-11. This is one of the few studies, the first conducted in Italy, on HPV infection in adolescents.
Urine testing is the easier way of detecting HPV infection in younger populations. Our data revealed a very low HPV
prevalence, and no infections were observed in the 12-year-old vaccine target population. The majority of infections
were seen in females aged 15-18 years. Overall, more than 50% and 30% of the potentially persistent HPV infections
detected in this group could have been prevented by the quadrivalent and the bivalent vaccines, respectively.
Citation: Bianchi S, Frati ER, Panatto D, Martinelli M, Amicizia D, et al. (2013) Detection and Genotyping of Human Papillomavirus in Urine Samples from
Unvaccinated Male and Female Adolescents in Italy. PLoS ONE 8(11): e79719. doi:10.1371/journal.pone.0079719
Editor: Julian W. Tang, Alberta Provincial Laboratory for Public Health/ University of Alberta, Canada
Received July 3, 2013; Accepted October 3, 2013; Published November 8, 2013
Copyright: © 2013 Bianchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was financed by the Italian Ministry of University and Research (project PRIN 2007; Grant number: 20074B5ZBC). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: elisabetta.tanzi@unimi.it
Introduction
Human Papillomavirus (HPV) is the cause of the most
common sexually transmitted infection and is associated with
the development of severe diseases, including invasive cervical
cancer, anogenital cancers and oral carcinomas, as well as
benign manifestations (e.g. genital warts) [1].
HPV vaccination has been introduced as a preventive
measure against cervical cancer, with young women as its
primary target [2]. Epidemiological data collected worldwide
have clearly shown that HPV infections are often acquired soon
after the first sexual intercourse [3,4] and adolescents who are
sexually active have particularly high rates of infection [5,6].
To date, two different vaccine formulations are able to
protect against persistent infection caused by the most
common oncogenic types (HPV-16 and -18) associated with
the development of cervical cancer, one of which also protects
against genotypes HPV-6 and -11, which are associated with
genital warts [7]. These two HPV vaccines have been licensed
by the U.S. Food and Drug Administration (FDA) in 2006 (the
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quadrivalent vaccine) and in 2009 (the bivalent vaccine) for use
in females 9-26 years and 9-25 years of age, respectively [8,9].
The Italian Medicines Agency (AIFA) approved both vaccines
in 2007 [10,11] and The Italian Superior Council on Health
drew up a vaccination schedule aimed at achieving 95%
vaccination coverage among 12-year-old girls over a five-year
period [12,13]. The 12- year-old cohort is the ideal target
population, since previous exposure to HPV is unlikely in this
age group, the median age at sexual debut being 16 years
among Italian females [14–16].
Noteworthy, recent evidence has shown that genital HPV
infections in adolescent females can occur even before the first
sexual intercourse, possibly owing to non-coital sexual
behaviours [17,18], autoinoculation [19] or other putative non-
sexual routes [20]. These observations underscore the
importance of primary prevention through vaccination at a very
young age.
The quadrivalent HPV vaccine was approved by the FDA
and the European Medicines Agency (EMA) also for males
9-26 years of age in 2009 and in 2011, respectively [21,22].
The American Academy of Pediatrics (AAP) recommends HPV
vaccination for boys, in order to obtain benefits both directly
(protection against genital warts and anal or oral HPV-
associated cancers) and indirectly (for females through herd
immunity) [23]. However, there is no consensus regarding the
advantages of male vaccination, and in many countries this
vaccination strategy remains a point of debate [22].
Although adolescents are the primary target of prophylactic
HPV vaccination programs, few epidemiological studies on this
age group are available. Additional data are therefore needed
in order to ascertain the HPV infection status of the adolescent
population. This knowledge would enable us to improve and
extend vaccination policy and to monitor changes in overall and
type-specific HPV prevalence rates as a result of HPV
vaccination.
To add new epidemiological data to this issue, we conducted
a study aimed at evaluating the prevalence of HPV infection
and the distribution of HPV genotypes among unvaccinated 11-
to 18-year-old boys and girls in Italy by means of a molecular
test suitable for HPV DNA detection and genotyping in urine
samples [24].
Materials and Methods
Ethics Statement
The study protocol used by all research units was approved
by the Ethics Committee of the Genoa Local Healthcare Unit
(LHU), Italy. All subjects gave assent to participate in the study.
Informed written consent was obtained from each 18 year-old
participant, or from parents or legal guardians if subjects were
under 18 years of age.
Study population
As part of a National Research Program of the Italian
Ministry of University and Research (MIUR), this study
recruited HPV-unvaccinated male and female adolescents at
sports medicine centres and at secondary schools located in
five cities of five different Regions: Turin (Piedmont), Milan
(Lombardy), Genoa (Liguria), Florence (Tuscany) in North/
Central Italy, and Sassari (Sardinia), Insular Italy. On the basis
of our preliminary studies (unpublished data), the expected
prevalence for HPV positivity in urine from adolescents was
around 1%, ranging from 0 to 3%. The power and the statistical
significance (two sided) were set at 90% and 5% level,
respectively. To determine the sample size in order to detect a
difference between proportions in a range of 1% (i.e. between
0.5% and 1.5%), at least 865 individuals were needed to be
enrolled. Individuals were proportionally sampled in the five
cities on the basis of resident population of 11-18 years of age.
Recruitment was conducted between September 2009 and July
2010 and each participant was asked to provide an anonymous
self-collected urine sample.
Sample collection and pre-treatment
Urine samples were collected in sterile containers,
maintained at room temperature (RT) and processed within 6-8
hours after collection at each participating centre. To obtain the
cellular component, at least 15 ml of each sample was pre-
treated by means of two different successive steps of
centrifugation and washing, as previously described [24] and
stored at -20°C until shipment to the centres of Milan
(Lombardy) or Cagliari (Sardinia) for molecular analyses.
DNA extraction and HPV DNA detection
HPV DNA was extracted from urine samples by means of the
NucliSENS® miniMAG® (bioMérieux, Lyon, France) extraction
kit. The concentration and purity of extracted DNA was
evaluated by using a spectrophotometer (Thermo Scientific
NanoDrop 2000; Thermo Fisher Scientific, Inc., Wilmington,
DE, USA). DNA quality was assessed by amplifying a 268 bp
(base pair) fragment of the ubiquitous β-globin gene. HPV DNA
was detected through PCR amplification of a 450 bp segment
of ORF L1 by using the degenerate primer pair ELSI-f and
ELSI-r in previously reported amplification reaction conditions
[24]. Each PCR run included positive controls (DNA extracted
from HPV-16 positive cells, CaSki) and negative (water)
controls.
The amplification products were visualized by means of
electrophoresis analysis of 2% agarose gel containing ethidium
bromide (0.5 mg/ml). Amplified product bands were compared
with molecular weight standards (DNA Molecular Weight,
Marker 100, Sigma-Aldrich, St. Louis, MO, USA). PCR
products of approximately 450 bp were subjected to restriction
fragment length polymorphism (RFLP) genotype analysis.
Restriction Fragment Length Polymorphism (RFLP)
analysis
Amplified products were digested with 1U of either RsaI,
DdeI or HaeIII, diluted in their respective buffers and incubated
at 37°C for 1 hour. Digestion products underwent
electrophoresis in 3% agarose gels, and restriction patterns
were compared with molecular weight standards (DNA
Molecular Weight, Marker 100+20, Sigma-Aldrich, St. Louis,
MO, USA). The pattern of fragments obtained from the three
digestive processes enabled to genotype to be identified [25].
The RFLP analysis can identify all genotypes included in the
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high risk clade (HR-clade) and low-risk genotypes (LR) of the
alpha genus according to the latest IARC classification system
[1].
Statistical analysis
Sample size was calculated using the statistical software
Stata 11.0 (StataCorp LP, College Station, Texas). HPV
prevalence was expressed as a crude proportion with
corresponding 95% confidence intervals (95% CI) calculated
using the Mid-p exact test assuming a normal distribution. A P-
value <0.05 was considered statistically significant (2-tailed
test). Statistical analysis was performed using OpenEpi,
version 3.01 [26].
Results
Demographic characteristics of the study population
A total of 870 adolescents aged 11-18 years (median age
15.5 years; IQR 14-17) were enrolled: 501 males (median age
16.0 years; IQR 14-17) and 369 females (median age 15.0
years; IQR 14-17). The final proportions of recruited individuals
in the five cities did not significantly differ from those expected
by sample calculation (Chi squared P = 0.35): 34.0% of urine
samples were collected from adolescents in Turin, 30.7% in
Milan, 21.4% in Genoa, and 8.6% and 5.3% from boys and
girls in Florence and Sassari, respectively. The median age
and the male/female distribution of the participants was
comparable between the cities involved.
HPV detection and genotyping
The β-globin gene was amplified from all 870 urine samples
collected, confirming the suitability of the extraction protocol.
Overall, 13 (1.5%; 95%CI 0.8-2.5) subjects were HPV DNA-
positive (11 females and 2 males).
The geographic distribution of HPV-positive adolescents was
as follows: 0.7% (2/296; 95%CI 0.1-2.2) in Turin, 1.5% (4/267;
95%CI 0.5-3.6) in Milan, 2.7% (5/186; 95%CI 1.0-5.9) in
Genoa, and 4.3% (2/46; 95%CI 0.7-13.6) in Sassari. HPV DNA
was not detected in samples collected from participants in
Florence (0/75; 95%CI 0.0-3.9). No significant differences were
observed.
Overall, 17 different infections were identified. In 69.2%
(9/13; 95%CI 41.3-89.4) of HPV DNA positive adolescents, the
infection was due to a single genotype and 88.9% (8/9; 95%CI
56.1-99.4) of the genotypes identified belonged to the HR-
clade. The remaining 4 subjects (30.8%; 95%CI 10.6-58.7) had
double infections, two of which were sustained by LR HPV
types and two by at least one genotype belonging to the HR-
clade.
HPV prevalence rates were significantly different between
genders (P<0.05): 0.4% (2/501; 95%CI 0.1-1.3) and 3.0%
(11/369; 95%CI 1.6-5.1) in males and females, respectively
(Table 1).
Among the 11 HPV DNA-positive girls (mean age 16.5 years,
range 14-18 years), only one (14 years old) belonged to the
11-14-year age-group (1/132, 0.8%; 95%CI 0.0-3.7). In the
female 15-18 age-group, the prevalence of HPV infection was
4.2% (10/237, 95%CI 2.2-7.4), significantly higher than that
detected in 11-14 age-group (P<0.05) (Table 1).
In the two HPV DNA-positive boys (14 and 18 years of age)
the infection was attributed to HPV-70. Approximately sixty-four
percent (63.6%; 95%CI 33.6-87.2) of the 11 HPV-positive girls
had a single infection and 4 (36.4%; 95%CI 12.8-66.4) were
infected with two genotypes. A total of 8 different genotypes
were detected among 15 infections identified in females:
HPV-16 (4/15, 26.7%; 95%CI 9.1-52.5), HPV-70 (3/15, 20.0%;
95%CI 5.3-45.4), HPV-6 and HPV-11 (2/15 each, 13.3%;
95%CI 2.3-37.5) and HPV-52, HPV-54, HPV-66 and HPV-87
(1/15 each, 6.7%; 95%CI 0.3-28.7) (Table 2).
The only HPV positive girl among the 11-14-year age-group
was infected with HPV-70. Sixty per cent of the positive girls in
Table 1. Prevalence of positive subjects, broken down by
gender and age-group (11-14 and 15-18 year-olds).
 Males Females Population Enrolled
 HPV-positive 95% CI HPV-positive 95% CI HPV-positive 95% CI
 subjects N(%)  
subjects N
(%)  
subjects N
(%)  
11-14
years 1/162 (0.6) 0.0-3.0 1/132 (0.8) 0.0-3.7 2/294 (0.7) 0.1-2.2
15-18
years 1/339 (0.3) 0.0-1.5 10/237 (4.2) 2.2-7.4 11/576 (1.9) 1.0-3.3
Total 2/501 (0.4) 0.1-1.3 11/369 (3.0) 1.6-5.1 13/870 (1.5) 0.8-2.5
doi: 10.1371/journal.pone.0079719.t001
Table 2. HPV infections and HPV infecting types in
females, broken down by age-group.
 
11-14 age-group
N (%) 95% CI
15-18 age-group N
(%) 95% CI
HPV INFECTIONS 1 (9.1) 0.5-37.3 10 (90.9) 62.7-99.6
Single infections 1 (9.1) 0.5-37.3 6 (54.5) 25.9-81.0
Multiple infections - - 4 (36.4) 12.8-66.4
HPV INFECTING 1 (6.7) 0.3-28.7 14 (93.3) 71.3-99.7
TYPES*     
HR group 1 - - 5 (33.3) 13.4-59.2
   HPV-16: 4 (26.7)  
   HPV-52: 1 (6.7)  
HR group 2A/2B 1 (6.7) 0.3-28.7 3 (20) 5.4-45.4
 HPV-70: 1 (6.7)  HPV-70: 2 (13.3)  
   HPV-66: 1 (6.7)  
Group 3/LR - - 6 (40) 18.1-65.5
   HPV-6: 2 (13.3)  
   HPV-11: 2 (13.3)  
   HPV-54: 1 (6.7)  
   HPV-87: 1 (6.7)  
*. According to the new IARC classification system [19]: Group 1 = carcinogenic to
humans; Group 2A (HPV-68) = probably carcinogenic to humans; Group 2B =
possibly carcinogenic to humans; Group 3/LR = not classifiable as carcinogenic to
humans.
doi: 10.1371/journal.pone.0079719.t002
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the 15-18 age-group were infected with the HPV-16 vaccine
type or co-infected with the LR- types HPV-6 and -11 included
in one of the two available vaccines.
Discussion
To our knowledge, no research has been planned with the
aim to evaluate HPV prevalence rates and genotypes
distribution in adolescents (11-18 year-old) in Italy prior to our
study. An extensive survey carried out in Italy on the
prevalence of high-risk HPV infection in women aged 15-73
years found a high prevalence (29.5%) in females between the
ages of 15-19 years, but the number of participants was very
low and they were all sexually active [27].
Worldwide, several studies have analysed adolescents within
a broader age range and by means of different methods and
types of sampling, making the results difficult to compare [28].
Only two studies have evaluated HPV infections in urine
samples collected exclusively from adolescents [29,30].
The present study identified a very low prevalence rate
(1.5%) of HPV infection among Italian adolescents, and found
a significantly lower prevalence in boys (0.4%) than in girls
(3.0%) (P<0.05). Our findings are consistent with those
reported in India by Hussain et al. [30] that showed a low HPV
prevalence rate in females and males between the ages of 8
and 17 years (3.2% and 2.1%, respectively), which increased
with age. In contrast, O'Leary et al [29] reported prevalence
rates of 1.1% and 1.4% in 11-14-year-old females and males
respectively, and of 15.2% and 3.9%, respectively, among
those aged 15-18 years in Scotland. The differences observed
could be explained by socio-economic, cultural, and
geographical differences, as well as by differences in the
modes of recruitment and methodologies used to establish
HPV infections.
In the present study, no significant differences were
observed in HPV infection prevalence rates among
adolescents residing in the five cities involved. A slightly, but
not significantly, higher percentage of infection was noted
among adolescents from Sassari. This may have been due to
the low number of samples analysed. However, the Sassari
area is known to have a high prevalence of HPV infections,
since high rates have been reported in women aged 15-54
years (35.9%) and 15-24 years (53.9%) undergoing Pap-
testing at public and private outpatient clinics [31].
In the 11-14-year age-group, only one female, aged 14
years, proved HPV-positive (1/132, 0.8%); this infection was
not associated with the vaccine types. No infections were
observed in the primary target vaccination group (12-year-old
females).
The majority (57%) of infections found in the 15-18-year-old
females were caused by genotypes belonging to the HR-clade,
with HPV-16 in 50% of cases. Overall, more than 50% and
30% of the potentially persistent HPV infections detected in this
group could have been prevented by the quadrivalent and the
bivalent vaccines, respectively.
The only two HPV-positive males were infected with HPV-70.
This genotype, that is classified by the IARC as "possibly
carcinogenic to humans" (group 2B), is not infrequently
detected in adolescents. Indeed, it has been shown to be
prevalent among males aged 15-18 years in Scotland [29].
Furthermore HPV-70 was responsible for 27% of infections in
the young females examined in our study. A more accurate
monitoring of the circulation of this genotype could better
determine its potential oncogenic role.
The method used in the present study appears to be
adequately able to identify HPV infections in urine samples,
since the pre-treatment required [24] allowed the detection of
genomic DNA that was valid for molecular testing in all
samples.
Several studies have validated urine sampling as an
alternative to cervical sampling-based methods for detecting
HPV infections in women [24,28,32,33]. Moreover, the urine
collection seems to be the best solution for young girls, being
non-invasive and more acceptable, bypassing the medical
examination and ethical issues. For these reasons this
approach can be used to carry out virological surveillance in
female adolescents in order to assess changes in HPV
prevalence rates and to determine genotypes circulation after
the introduction of prophylactic vaccination.
In males, the analysis of urine samples for the detection of
HPV remains controversial, since there is no ‘gold standard’
sampling method, as there is in females (i.e. analysis of
cervical swabs), and few studies have compared the sensitivity
of HPV detection in urine with that of detection in other
urogenital samples (e.g. penile/urethral swabs). Furthermore,
no studies have compared this detection method with other
techniques in male adolescents. Therefore, a consensus
regarding which sampling method in males is most effective is
still lacking [34,35].
Although the data presented in this report support the
adequacy of urine sampling for the diagnosis of HPV infections
in males, the prevalence of HPV infections reported may be
underestimated owing to low viral DNA concentrations in urine
or to presence of HPV infections in anatomical sites not
covered by urine transit [28,35].
A further limitation of the study was the lack of information on
the socio-demographic characteristics, sexual debut and
sexual habits of the subjects studied. However, this was not the
primary objective of the study, which was designed to evaluate
the overall and type-specific HPV prevalence in an
unvaccinated adolescent population in Italy.
Conclusions
This is one of few studies, and the first conducted in Italy,
designed to establish HPV prevalence and genotypes
distribution in an adolescent population. The data reported
suggest a very low HPV prevalence rate in the age-group
studied. The fact that no infections were observed in the
primary target vaccination group (12-year-old females)
indicates that the prevention strategy currently in force in Italy
is appropriate. Furthermore, the low prevalence of HPV
infections observed in 15-18-year-old females supports the
multi-cohort strategy of vaccination adopted by several Italian
Regions [36], also considering that more than 50% and 30% of
the potentially persistent infections detected in this age-group
HPV Prevalence in Italian Adolescents
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could have been prevented by the quadrivalent and bivalent
formulations, respectively.
Molecular testing of urine samples is the non-invasive and
easier way to determine the HPV infection status in the
youngest age-groups. This is essential to establishing the
baseline HPV prevalence, which is a prerequisite to monitoring
the impact of HPV vaccination at the population level. Future
studies will have to be conducted on a larger population of
adolescents representing different geographical areas and
socio-cultural features in order to provide a more accurate
estimate of HPV infection status in this age group.
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